Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Mepolizumab - GlaxoSmithKline

Next Previous
Drug Profile

Mepolizumab - GlaxoSmithKline

Alternative Names: 240563; Bosatria; Mepolizamab; Nucala; SB-240563

Latest Information Update: 03 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GlaxoSmithKline
  • Developer GlaxoSmithKline; GSK; McMaster University; National Institute of Allergy and Infectious Diseases
  • Class Anti-inflammatories; Antiallergics; Antiasthmatics; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action Interleukin 5 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hypereosinophilic syndrome; Churg-Strauss syndrome
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Asthma; Nasal polyps
  • Registered Chronic obstructive pulmonary disease; Churg-Strauss syndrome; Hypereosinophilic syndrome
  • Phase II Eosinophilic oesophagitis
  • Discontinued Atopic dermatitis

Most Recent Events

  • 03 Jun 2025 Planned Prescription Drug User Fee Act (PDUFA) date for Chronic obstructive pulmonary disease (Adjunctive treatment) in USA (SC) is 2018-09-07
  • 22 May 2025 Preregistration for Chronic obstructive pulmonary disease (Adjunctive treatment) in China (SC) before May 2025
  • 22 May 2025 Registered for Chronic obstructive pulmonary disease (Adjunctive treatment) in USA (SC)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top